Brief: 4DMT Presents Additional Positive Interim Data From Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial In Patients With Wet AMD At ASRS 2023

4D Molecular Therapeutics

29/07/2023 17:03

July 29 (Reuters) - 4D Molecular Therapeutics Inc
 FDMT.O :
    * 4DMT PRESENTS ADDITIONAL POSITIVE INTERIM DATA FROM
INTRAVITREAL
4D-150 PHASE 1/2 PRISM CLINICAL TRIAL IN PATIENTS WITH WET AMD
AT ASRS 2023
    * DOSE RESPONSE DEMONSTRATED IN FAVOR OF HIGHEST TESTED DOSE
OF
3E10 VG/EYE
    * 4D MOLECULAR THERAPEUTICS - ASSESSMENT OF OUTCOMES BEYOND
36
WEEKS IN 3E10 VG/EYE DOSE COHORT SHOWED DURABLE REDUCTION IN
SUPPLEMENTAL ANTI-VEGF INJECTIONS
    * 4D MOLECULAR THERAPEUTICS - PHASE 2 DOSE EXPANSION INITIAL
INTERIM EFFICACY AND SAFETY DATA PRESENTATION EXPECTED AT
MEDICAL CONFERENCE IN H1 2024

Source text for Eikon:  ID:nGNX6DqFjJ 
Further company coverage:  FDMT.O 

 ((Reuters.Briefs@thomsonreuters.com;))